Abivax S.A. (ABVX) — Analyst outlook / Analyst consensus target is. Based on 9 analyst ratings, the consensus is bullish — 9 Buy.
The consensus price target is $145.67 (low: $110.00, high: $176.00), representing an upside of 15.8% from the current price $125.80.
Analysts estimate Earnings Per Share (EPS) of $-2.80 and revenue of $0.01B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-2.80 vs est $-2.80 (beat +0%). 2025: actual $-4.65 vs est $-3.87 (missed -20%). Analyst accuracy: 92%.
ABVX Stock — 12-Month Price Forecast
$145.67
▲ +15.79% Upside
Average Price Target
Based on 9 Wall Street analysts offering 12-month price targets for Abivax S.A., the average price target is $145.67, with a high forecast of $176.00, and a low forecast of $110.00.
The average price target represents a +15.79% change from the last price of $125.80.
Highest Price Target
$176.00
Average Price Target
$145.67
Lowest Price Target
$110.00
ABVX Analyst Ratings
Buy
Based on 9 analysts giving stock ratings to Abivax S.A. in the past 3 months
EPS Estimates — ABVX
92%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$2.80
vs Est –$2.80
▲ 0.0% off
2025
Actual –$4.65
vs Est –$3.87
▼ 16.7% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — ABVX
83%
Analyst Accuracy
Accurate
1 year compared
Actual vs Estimate
2024
Actual $0.011B
vs Est $0.009B
▲ 16.9% off
Revenue Trend
Revenue has declined over the period shown. Analysts expect stable revenue going forward.
